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Persistent infections caused by such agents as the human immunodeficiency virus, hepatitis B virus, Epstein–Barr virus,
etc., present formidable medical problems. A defining characteristic of these infections is that anti-viral cytotoxic T
lymphocytes (CTL) may be lost or, if present, fail to clear the infection. Here we report a vaccination strategy which was
successful in generating lytic CTL in persistently infected mice. Vaccination with an immunodominant CTL epitope derived
from the nucleoprotein of lymphocytic choriomeningitis virus (LCMV) delivered in the form of a lipopeptide incorporating a
universal CD4 helper epitope successfully induced lytic MHC-restricted CTL in mice persistently infected with LCMV since
birth. However, induction of such CTL did not eliminate the virus, most likely because the CTL were generated at low
frequencies and had 2 to 3 logs lower affinity than CTL generated in uninfected mice inoculated with the vaccine. Both CTL
populations from either uninfected or persistently infected mice produced significant and similar amounts of interferon-g and
IL-6. Vaccine-induced low-affinity CTL were still inadequate at complete removal of the virus when combined with LCMV-
specific CD4 helper T lymphocytes. Thus, our results establish that CTL can be generated in persistently infected mice and
that a crucial factor for clearing viral infection is the affinity of the CTL. © 2000 Academic Press
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(INTRODUCTION
For a virus to persist successfully it must avoid recog-
nition and elimination by the host’s immune system. A
primary strategy for clearing a persistent viral infection is
priming or repriming the compartment of the host’s im-
mune system that can handle the virus during an acute
infection (Whitton and Oldstone, 1999). Evidence from
genetically deficient humans (Flake and Zanjani, 1999;
Greenberg and Riddell, 1999) or experimentally deficient
mice (Kagi et al., 1996) as well as adoptive transfers
primarily in mice (Ahmed et al., 1984; Oldstone et al.,
1986; Tishon et al., 1995) and humans (Riddell and
Greenberg, 1997) indicate that the primary cell involved
in clearance of a virus from cells or tissues is the cyto-
toxic T lymphocyte (CTL). The mechanism of clearance
involves the lytic activity of such cells, CD4 help, and in
some instances their release of cytokines like interferon
(IFN)-g (Tishon et al., 1995) and TNF-a (Guidotti et al.,
996).
A classic model of viral persistence is represented
y lymphocytic choriomeningitis virus (LCMV) infec-
ion of its natural host, the mouse. After infecting
uring either the fetal or the neonatal periods, LCMV
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411eplicates in the thymus, and most T cells responsive
o the virus are deleted by negative selection. Inability
o detect functional anti-LCMV CTL activity in persis-
ently infected mice (Binder et al., 1998; Moskophidis
t al., 1993, 1994) by one laboratory led to the argu-
ent that they had all been eliminated by immunolog-
cal tolerance (Stitz and Zinkernagel, 1984) through
egative selection due to viral infection of the thymus.
owever, recently the physical presence of LCMV-
pecific CD8 T cells in mice whose persistent infection
as initiated in adulthood has been detected by stain-
ng with MHC-epitope tetramers, but these cells ap-
eared functionally inactive (Zajac et al., 1998a,b).
imilarly, studies by our laboratory (von Herrath et al.,
994a,b) and others (Ashton-Richardt et al., 1994) dem-
nstrated that negative selection due to antigen ex-
ression in the thymus is incomplete and allows for
he emergence of antigen-specific low-affinity T cells
nto the periphery: transgenic mice that express LCMV
rotein in the thymus (von Herrath et al., 1994a,b)
elect out high-affinity CTL; however, low-affinity anti-
CMV CTL are present in the periphery and can be
ctivated in vivo.
A lack of peripheral CTL activity has also been noted
n humans who chronically carry hepatitis B viruses
HBV) (Chisari and Ferrari, 1995; Rehermann et al., 1996).
ipopeptide vaccination can induce CTL in these individ-
als, resulting in a modest decrease, but not elimination
0042-6822/00 $35.00
Copyright © 2000 by Academic Press
All rights of reproduction in any form reserved.
h
p
l
T
m
1
e
a
s
f
n
(
w
f
l
l
f
t
g
s
L
R
p
t
i
f
p
f
p
w
1
m
2
2
a
412 VON HERRATH ET AL.of, the virus, likely because the magnitude of the re-
sponses was low (Heathcote et al., 1999; Livingston et
al., 1999; Vitiello et al., 1995). In patients positive for the
uman immunodeficiency virus (HIV), CTL activity dissi-
ates over time, in association with an increase in viral
oad and occurrence of clinical AIDS (Hay et al., 1999).
herefore, adoptive T-cell transfers might benefit hu-
ans with persistent infections like HIV (McKinney et al.,
999; Tan et al., 1999), Epstein–Barr virus (Steven, 1997)
and cytomegalovirus (Walter et al., 1995). Adoptive im-
munocytotherapy is currently impractical on a large
scale, because of the difficulties of MHC restriction and
matched donors location. For these reasons, devising
strategies to “revitalize” or regenerate autologous effec-
tor CTL in vivo by vaccination is a worthwhile goal
(Ahmed et al., 1984; Oldstone et al., 1986).
To test whether a vaccine could generate lytic CTL and
determine their ability to clear a persistent infection, we
designed a model in which several factors could be
manipulated. Our hypothesis was that vaccination with
an MHC class I-restricted lipopeptide containing a uni-
versal CD4 helper epitope would activate sufficient
amounts of antiviral CTL and, if viral titers were de-
creased concurrently, provision of CD4 help might en-
able anti-viral CD8s to successfully resolve the infection.
The model system we chose was the H-2d mouse per-
sistently infected with LCMV at birth (Borrow and Old-
stone, 1997; Buchmeier et al., 1980). These mice do not
spontaneously generate measurable amounts of CTL
activity against LCMV and remain persistently infected
throughout their lives. Yet, their survival rate is compa-
rable to that of uninfected mice. Total clearance of infec-
tious virus and viral nucleic acid sequences has been
achieved by adoptive transfer of immune, syngeneic
splenocyte populations that require the participation of
functional CD81 effector cells, CD4 helper cells, and the
mandatory inclusion of IFN-g (Ahmed et al., 1984; Binder
t al., 1998; Moskophidis et al., 1993, 1994; Oldstone et
l., 1986; Planz et al., 1997; Tishon et al., 1995). Because
pecific peptides located within the viral proteins that
orm CTL epitopes are known and, when used to immu-
ize uninfected mice, generate anti-LCMV-specific CTL
Klavinskis et al., 1990; Whitton et al., 1989, 1993), we
were able to assess whether CTL could be generated
and amplified in persistently infected mice using CTL
epitope peptide vaccines. Here we report the vaccination
of persistently infected mice with a lipopeptide vaccine
with or without concurrent antiviral ribavirin therapy.
Ribavirin therapy has been shown to have some clinical
effectiveness in reducing virus load in human infections
(Fisher-Hoch et al., 1995) and was shown by de la Torre
and Oldstone (unpublished) to reduce LCMV load by 1 to
2 logs. The vaccine induced significant numbers of lytic
anti-LCMV CTL in the persistently infected mice, and
these CTL released amounts of cytokines like IFN-g that
l
mere equivalent to those in similarly vaccinated, unin-
ected mice. Concurrent ribavirin therapy, as anticipated,
owered the viral load by 2 logs, but the remaining 2 to 3
ogs of virus indicated that the generated anti-LCMV CTL
ailed to terminate the infection. The cause was that
hese CTL were of 2 to 3 logs lower affinity than CTL
enerated in uninfected, vaccinated hosts. The ability of
uch CTL to clear LCMV was not improved by providing
CMV-specific CD4 help.
RESULTS
ibavirin treatment lowers viral titers in LCMV
ersistently infected mice
By using ribavirin therapy to decrease viral titers in
he thymus and peripheral organs of mice persistently
nfected with LCMV before vaccination, we hoped to
acilitate the activation of viral–antigen-specific lym-
hocytes. Indeed, this strategy was modestly success-
ul in that these animals’ viral titers diminished up to 2
FIG. 1. Ribavirin treatment lowers viral titers in LCMV persistently
infected mice by 2 logs. Groups of three Balb/c H-2d mice each were
ersistently infected at birth with LCMV ARM clone 53b. When the mice
ere 60 days old, daily ribavirin treatment was started at doses of 50,
00, 200, and 400 mg/kg body weight ip. LCMV serum titers (A) were
easured by plaque assay before treatment and at weekly intervals for
8 days. Body weight of mice (B) was assessed twice weekly. Doses of
00 and 400 mg/kg were terminated because of clinical toxicity. Means
re shown; SE was less than 10% for each value displayed.ogs after daily injections intraperitoneally (ip) of 100
g ribavirin/kg (Fig. 1A). Although viral titers in indi-
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413CTL AND PERSISTENT VIRAL INFECTIONvidual mice varied less than 0.5 logs, overall titers
fluctuated from 105.2 to 106.1 PFU/ml prior to treatment.
e then plotted the reduction of virus load after as-
essing percentage reduction per individual mouse as
he mean decrease of the group (three mice per group,
xperiment done twice). Despite the lowering of viral
iters by 1 to 2 logs, significant amounts of virus still
ersisted in ranges of 102–103.5 PFU/ml per mouse.
owever, the ribavirin dose of 100 mg/kg daily ip
roduced neither the toxicity nor the weight loss seen
t higher doses (Fig. 1B).
accination with an MHC class I-restricted LCMV
ucleoprotein (NP) 1 helper (Padre) lipopeptide
lipopeptide vaccine) expands the LCMV-specific
ytic CTL population in persistently infected
ice but does not clear virus
To induce specific CTL in mice persistently infected
ith LCMV, we inoculated the animals with the newly
ormulated lipopeptide vaccine three times. We were
ble to induce functional (lytic) LCMV NP-specific CTL as
ested in a 51Cr release assay 28 days after the last
vaccination. Uninfected mice given the vaccine produced
10- to 15-fold fewer CTL than mice acutely infected with
whole virus (Table 1). Furthermore, and most interest-
ingly, lytic LCMV-specific CTL were induced in persis-
tently infected mice. In comparison, persistently infected
vaccinated mice had only 4- to 5-fold fewer functional
CTL than the uninfected vaccinated mice (Table 1). How-
T
Lipopeptide Vaccine Induces Significant Numbe
Groups of H-2d mice
Treatment
Uninfected N
lipopeptidebNP RV
Persistently LCMV 2 1 0
infected 1 1 0
1 2 0
Uninfected 2 2 0
2 1 1 0
2 1 2 0
LCMV infection (day 7) 0
Note. NP, mice received treatment (33) with NPd lipopeptide. RV, mic
he CTL assay the mean and SE are shown; for the LDA (pCTL) all value
he last lipopeptide vaccination.
a CTL assay, 5- to 6-h 51Cr-release assay; E:T ratio 5 10:1; see Meth
b Lipo-NPb peptide-coated targets. This peptide contained the identic
instead of the H-2d-restricted NP peptide it contained the H-2b-restrict
c pCTL frequency analysis as described under Methods. Three miceever, subsequent testing of these CTL’s ability to clear
virus from the persistently infected mice indicated noreduction in the viral load, as Fig. 2 illustrates. These
results showing induction of significant numbers of lytic
CTL suggested that there was a qualitative in addition to
the quantitative defect(s) in CTL generated in persistently
infected mice.
LCMV NP CTL generated in persistently infected
mice by vaccination are low in affinity and fail to
clear virus upon adoptive transfer
We next added serial dilutions of the LCMV NP
peptide to splenocytes harvested from persistently
ytic LCMV pCTL in Persistently Infected Mice
ctivity on targetsa
pCTL frequencyc in H-2d
targets
LCMV-infected
H-2d (%) H-2b (%)
3 6 1 0 nil (,1:50,000)
45 6 8 0 1:11,000; 1:9,800; 1:12,600
52 6 11 0 1:12,000; 1:13,000; 1:11,300
3 6 2 0 nil (,1:50,000)
70 6 14 0 1:3,200; 1:4,200; 1:2,500
67 6 15 0 1:2,800; 1:2,400; 1:3,100
65 6 16 3 6 2 1:350; 1:110; 1:450
ived ribavirin treatment. The experiment was repeated three times. For
isplayed. CTL assays and LDA analyses were performed 28 days after
er epitope and lipid tail as those used for the NP vaccine peptide, but
peptide (FQPQNGQFI).
roup were used; two separate experiments were performed.
FIG. 2. Lipopeptide vaccine does not result in viral clearance.
Groups of eight Balb/c mice each were persistently infected with
LCMV ARM 53b at birth. Treatment groups received saline, ribavi-
rin 6 LCMV NP CTL lipopeptide vaccine alone (NP), or a combina-
tion of RV 1 NP. RV treatment began when the mice were 60 days
old (day 0), at a dose level of 100 mg/kg/day daily ip. NP was
inoculated three times in biweekly intervals, starting 14 days after
the ribavirin treatment. RV treatment reduced the viral serum titersABLE 1
rs of L
CTL a
Pb
(%)
e rece
s are d
ods.
al helpby 2 logs, whereas additional application of NP or inoculation of NP
alone did not affect viral titers.
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414 VON HERRATH ET AL.infected and uninfected mice given vaccine and mea-
sured affinity using log dilutions of peptides in 51Cr
release assays. The results in Table 2 demonstrate
that the NP CTL derived from persistently infected,
vaccinated mice had 2–3 logs lower affinity than those
from immunized but uninfected mice. We then assayed
those low-affinity CTL for the ability to clear virus upon
adoptive transfer. Low-affinity CTL obtained from per-
sistently infected mice and expanded in vitro or lym-
phocytes harvested directly ex vivo from spleens of
persistently infected mice after vaccination were
transferred into persistently infected syngeneic recip-
ients. As Fig. 3 depicts, these low-affinity cells failed to
lower viral titers in vivo. Thus, vaccination induced
ow-affinity CTL in persistently infected mice, but these
TL were incapable of lowering viral titers in vivo,
espite exhibition of good antiviral lytic activity in vitro.
he cytokine profiles are alike in low-affinity LCMV
P CTL induced by vaccination and high-affinity CTL
resent in uninfected LCMV immune hosts
In addition to lytic CTL function, specific LCMV CD4
cell help (Berger et al., 2000; Tishon et al., 1995),
T
Lipopeptide Vaccine Induces 4-logs Lower Affinity CTL in Pe
Persistent LCMV infection
Treatment
NP RV 1024
1 1 1 43
1 1 2 45
1 2 1 0
2 1 1 55
2 1 2 47
Note. Splenocytes were harvested from persistently infected Balb/c
weeks after three-time injection with the lipopeptide vaccine. The pe
a CTL assay, 5- to 6-h 51Cr-release assay; E:T ratio 5 12:1.
FIG. 3. Adoptive transfer of low-affinity splenocytes generated by
ipopeptide vaccine fails to clear virus from persistently infected recip-
ents. Groups of four Balb/c mice each were persistently infected with
CMV ARM 53b at birth and used as recipients for transferred spleno-
ytes from LCMV-immune mice, splenocytes from LCMV persistentlynfected mice, and in vitro-expanded (for 2 weeks) low-affinity CTL
arvested from persistently infected, lipopeptide vaccine-treated mice.IFN-g, and perhaps other cytokines (Oldstone et al.,
1986; Tishon et al., 1995) are mandatory to terminate
iral infection. Therefore, we tested whether the failure
f low-affinity CTL to eliminate virus was associated
ith a cytokine-related defect. Comparison of cytokine
rofiles produced by low- and high-affinity CTL by in
itro ELISA analysis clearly showed that both types of
TL produced equivalent amounts of cytokines (Fig.
). That is, significant amounts of IFN-g, interleukin
IL)-4, IL-2, and IL-6 and very low but equivalent
mounts of IL-12 were made by low-affinity CTL gen-
rated in persistently infected mice, as well as high-
ffinity CTL in LCMV immune mice. Thus, an altered
ytokine profile does not explain the lack of viral
learance after lipopeptide vaccine, focusing the de-
ect to the affinity of CTL.
tly Infected Hosts but High-Affinity CTL in Uninfected Mice
CTL activitya at peptide concentration (%)
1026 1027 1028 1029 10210
0 0 0 0 0
0 0 0 0 0
0 0 0 0 0
34 38 29 14 0
28 33 35 20 0
ive/group) at the age of 130 days and from uninfected controls always
sed was LCMV NPd peptide RPQASGVYM.
FIG. 4. Low- and high-affinity CTL produce similar cytokine profiles
after stimulation with LCMV antigen. ELISAs were performed as de-
scribed using supernatants from 7-day splenocyte cultures of mice
treated with the lipopeptide vaccine. Low-affinity CTL were isolated
from mice persistently infected with LCMV ARM 53b since birth, and
high-affinity CTL came from uninfected mice vaccinated with the li-
popeptide vaccine. Each bar represents 1 SE; the mean of four samples
is displayed. Dark bars, cytokine production by splenocytes containing
high-affinity CTL from uninfected mice; shaded bars, cytokine produc-ABLE 2
rsisten
1025
21
17
0
31
35
mice (ftion by splenocytes containing low-affinity CTL from persistently in-
fected mice.
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415CTL AND PERSISTENT VIRAL INFECTIONCD4 helper LCMV-immune lymphocytes and antigen-
presenting cells (APCs) do not enable low-affinity
CTL to clear persistent infection
Last, we tested whether the addition of LCMV-specific
CD41 T cells would assist low-affinity CTL to clear the
persistent virus infection, since MHC-restricted LCMV
CD41 T cells are an absolute requirement for the in vivo
aintenance of effector CD81 antiviral CTL activity
(Berger et al., 2000; Jamieson et al., 1991; Matloubian et
l., 1994; Tishon et al., 1995; von Herrath et al., 1995).
Quantitatively, one virus-specific CD4 cell per 50 virus-
specific CD8 cells is required (Berger et al., 2000). Alter-
ations in the CD41 helper compartment have also been
ssociated with low responses to vaccination in humans
Livingston et al., 1999). To ensure that efficient CD4 help
was present, we provided a relative excess of LCMV-
specific CD41 T cells (5 3 106 cells per mouse total
containing approximately 5 3 104 LCMV-specific lympho-
cytes) for low-affinity CD81 T cells (host) in adoptive
transfer experiments, as shown in Fig. 5. However, no
reduction of viral titers was observed (Fig. 5).
DISCUSSION
We noted that for the first time significant numbers of
antiviral CTL with lytic activity could be induced and
expanded in mice persistently infected with LCMV since
birth. Our strategy was to inoculate such mice, when
adults, with a lipopeptide vaccine that induced LCMV-
specific CTL but also contained a CD4 helper epitope. In
response, lytic LCMV NP-specific CTL were generated.
FIG. 5. Provision of a relative excess of LCMV-immune CD41 helper
ymphocytes and APCs does not enable low-affinity CTL to clear per-
istent LCMV infection. The lipopeptide vaccine and ribavirin were
ombined with LCMV-immune CD4 cell transfers and APCs (CD8-
epleted LCMV immune splenocytes) in order to provide sufficient CD4
elp. The lipopeptide vaccine (NPd) was given three times in biweekly
ntervals (days 14, 28, and 42). Persistently infected mice (four/group)
eceived cotransfers of 1.65 3 107 CD8-depleted (Dynabeads, depletion
99.8% by FACS confirmed) splenocytes containing 5 3 106 CD4 cells
fter three-time immunization with lipopeptide vaccine. Control mice
eceiving LCMV immune splenocytes cleared the persistent infection
ithin 14 days (see Fig. 3, data not displayed here).Further, cytokines were measurable in amounts equiva-
lent to those made by splenocytes from uninfected miceinoculated with the lipopeptide vaccine. These results
indicate that vaccination can elicit lytic antiviral CTL in
the face of persistent infection. However, despite gener-
ating lytic and cytokine-producing CTL activity by vacci-
nation, the produced anti-LCMV CTL did not clear the
infection by themselves alone or after a 2-log reduction
of viral titers provided by anti-viral chemotherapy with
ribavirin or after providing external LCMV-specific CD4
help. Apparently, although the viral load was reduced by
2 logs, the 103 PFU logs of virus that remained most likely
tolerized antiviral high-affinity CTL by thymic-negative
selection or peripheral tolerance mechanisms. We found
that the remaining CTL were of low affinity and unable by
adoptive transfer to clear the persistent viral infection as
effectively as similar numbers of 2- to 3-log higher-affinity
CTL. Attempts to overcome this low affinity by providing
costimulation signals, systemic APC activation, or opti-
mized presentation to the MHC class I pathway by using
a ubiquitinated DNA-plasmid construct are currently un-
der investigation.
Our finding reported here for mice persistently in-
fected with LCMV as newborns compliments the recent
report from Ahmed’s laboratory (Zajac et al., 1998a) re-
garding adult mice that were infected with immunosup-
pressive LCMV variants such as t1b to show that virus-
specific CD8 T cells can persist indefinitely and can be
recovered from a chronically infected host. However,
Zajac et al. (1998a) were unable to show functional CTL
lysis or secretion of IFN-g in their model despite treat-
ment with PMA and ionomycin, agents that activate pro-
tein kinases and elevate intracellular Ca21 levels. In
ontrast, by use of the CTL epitope vaccine coupled with
universal CD41 T cell helper epitope, we were able to
generate LCMV-specific CD81 T cells that both were lytic
n a 51Cr release assay and secreted IFN-g. Thus, deliv-
ery of a CTL epitope in a different molecular and immu-
nologic context (lipid adjuvant and CD41 helper epitope)
s sufficient to overcome “T cell tolerance” in persistent
nfection. Probably, the remaining low-affinity CTL do not
ee the ubiquitous viral antigens in the “right” context,
.e., on activated, professional APCs providing sufficient
ostimulatory signals. This results in their lack of activa-
ion but can be overcome by supplying external signals
hat activate APCs, such as CD41 help and adjuvants. In
this context it is of interest to note that Alexander and
colleagues (Alexander et al., 1998) have reported that the
frequency of stimulation and the density of antigen on
the surface of antigen-presenting cells are capable of
modulating the affinity of the resulting primary CTL re-
sponse. It will be important, in future studies, to explore
different immunization regimens which specifically opti-
mize the affinity of resulting CTL. In this respect, this
study provides an important tool for vaccine develop-
ment, in suggesting a practical way to test and, thus,
optimize immunotherapeutic vaccination strategies.
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416 VON HERRATH ET AL.Whether the number of LCMV NP CTL precursors
(pCTL) induced by our lipopeptide vaccine were suffi-
ciently high to clear the infection needs further consid-
eration. Previously, we have found in an H-2b adoptive
transfer model that a minimal number of 350,000 antigen-
specific CD81 and 7000 antigen-specific CD41 cells was
required for efficient virus clearance from all organs of
the persistently infected recipients (Berger et al., 2000). It
should be noted, however, that only about 15 of antigen-
specific CD81 T cells also scored positive in a CTL LDA
analysis. Thus, about 70,000 pCTL in conjunction with
appropriate CD4 help constituted the lower limit for ef-
fective virus control. In the present study, only about 9000
pCTL were found in the spleens of vaccinated, persis-
tently infected mice (average spleen cell count, ;1 3 108
cells; pCTL, 1/11,000 spleen cells) and repeated vacci-
nation did not increase the pCTL frequencies markedly.
While other lymphocyte compartments such as bone
marrow and lymph nodes are likely to also contain NP-
specific pCTL, the critical threshold of about 70,000 pCTL
may not be reached considering the ninefold reduced
numbers of pCTL (9000) in the spleen alone. In contrast,
the pCTL numbers found in spleens of vaccinated unin-
fected mice (;33,000) may be sufficient, taking addi-
tional lymphocyte compartments into account. Since
CD41 T cell help is a crucial component for control of
persistent virus infection, we investigated whether pro-
vision of LCMV-specific CD41 T cells would affect virus
iters in vaccinated, persistently infected mice. To assure
ufficient specific CD41 T cells, an excess of CD41 T
ells (as part of a CD8-depleted population) was adop-
ively transferred in conjunction with the lipopeptide vac-
ination. In the transfer population, about 1/100 CD41 T
cells was specific for LCMV (data not shown, compare to
Berger et al., 2000). However, no reduction of virus titers
was observed (Fig. 5). In addition to the reduced num-
bers of pCTL induced by vaccination, CTL affinity is likely
an important factor that hampered resolution of persis-
tent infection.
The generation of relatively low-affinity CTL by vaccine
may result from the expression of viral antigen in the
thymus (Jamieson et al., 1991) or the high systemic load
of LCMV antigen leading to peripheral tolerance (Sprent
and Webb, 1995). LCMV antigen is found at high levels in
the thymuses of persistently infected mice (Jamieson et
al., 1991). Further, in transgenic models manipulated to
express LCMV protein by the use of the Thy1.2 promoter
or in mice expressing the viral protein in the b cells of the
slet of Langerhans and also in the thymus, deletion of
igh-affinity but not low-affinity antiviral CTL occurred
von Herrath et al., 1994a,b). Interestingly, when viral
rotein was expressed only in the b cells but not in the
thymus, coexpression of the costimulatory molecule B7.1
in the islets led to the spontaneous activation and killing
of b cells by antiviral CTL. In contrast, and similar to ourfindings here, when the viral transgene was also ex-
pressed in the thymus, B7.1 failed to spontaneously ac-
tivate CTL to damage b cells CTL in vivo (von Herrath et
al., 1995). Consequently, substantially lowering the viral
load from the thymus preceding vaccination appears to
be important for the latter’s success. However, the 100-
fold decrease achieved by using ribavirin, a drug effec-
tive against RNA viruses through inhibition of viral en-
zyme synthesis, was insufficient to correct the problem,
since a large amount of virus remained after its admin-
istration. In this respect, it is likely that a more stringent
test of this approach will come from clinical trials in HBV,
HIV, or HCV chronically infected individuals. It has been
shown that treatment with antiviral drugs, such as
HAART therapy in the case of HIV (Saag and Kilby, 1999)
and LAMIVUDINE in the case of HBV, lowers viral titers
to virtually undetectable levels (Jarvis and Faulds, 1999).
Concomitant to the reduction in viral titers, immune re-
activity was reacquired (Boni et al., 1998). Finally, in the
ase of HCV, perhaps as a result of the low viral burden,
eripheral or in situ CTL tolerance appears to be less
roblematic (Mast et al., 1999).
In conclusion, we report here the induction of lytic,
IFN-g-producing CTL in mice persistently infected with
CMV. Based on quantitative knowledge stemming from
ransfer studies in the LCMV system (Berger et al., 1999),
he frequency of pCTL induced by lipopeptide vaccina-
ion may not have reached the critical threshold required
or virus control. In addition, the CTL induced were likely
oo low in affinity to accomplish viral clearance, an ob-
tacle that could not be overcome by lowering viral titers
r providing CD41 help. Our results represent an impor-
tant first step toward development of effective strategies
for therapeutic vaccination against chronic viral dis-
eases, as it demonstrates that CTL responses can be
“rescued” in the face of persisting viral antigens. Our
data suggest CTL affinity as a crucial parameter for
vaccination studies and improving affinity important for
therapeutic interventions.
METHODS
Viral strains and persistent infection. Virus stocks con-
sisted of LCMV Armstrong (ARM) (Clone 53b). Viruses
were plaque-purified three times and stocks were pre-
pared by single passage on BHK-21 cells (LCMV ARM)
(Whitton et al., 1989, 1993). Persistent infection was
achieved by intracranial injection (i.c.) of newborn mice
with 5 3 103 PFU of LCMV (Borrow and Oldstone, 1997).
Viral titers were quantitated by plaquing on Vero cells
(Dutko and Oldstone, 1983; von Herrath and Whitton,
1999).
Mouse strains. All studies were performed in Balb/c
dH-2 mice obtained from the rodent breeding colony at
The Scripps Research Institute.
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417CTL AND PERSISTENT VIRAL INFECTIONRibavirin application. Ribavirin (1-b-D-ribofuranosyl-
,2,4-triazole-3-carboxamide, Vira-zole) is an analogue of
he natural nucleoside antiviral drug pyrazomycin and
mpedes viral replication by inhibition of viral enzyme
ynthesis. It was kindly supplied by ICN Pharmaceuticals
Costa Mesa, CA). The maximally tolerable dose, as
efined by a maximum weight loss of 10%, for long-term
reatment in mice persistently infected with LCMV was
itered at 100 mg/kg daily ip (4 to 6 mice per group).
Synthesis, quantification, and administration of li-
opeptide vaccine. The single H-2d-restricted NP immu-
nodominant domain of LCMV (aa 118–126, RPQASGVYM)
was linked to a universal MHC class II helper epitope
derived from Padre (AKXVAAWTLKAAA). After peptide
synthesis was performed in accord with standard t-BOC
or F-moc solid-phase synthesis methods, purity was
.95% as determined by standard HPLC. Preformed, then
attached to a palmitic acid tail (Vitiello et al., 1995),
symmetrical anhydride of palmitic acid was coupled to
the amino terminus of the resin-bound peptide. Stock
solutions of peptides were dissolved in DMSO at con-
centrations of 20 mg/ml and diluted in PBS immediately
before use. Mice received three injections of 20 mmol of
lipopeptide per injection sc in biweekly intervals.
CTL assays. CTL activity was measured in a 5- to 6-h
in vitro 51Cr release assay as described (von Herrath et
al., 1994b; Whitton et al., 1993). To evaluate CTL recog-
nition and lysis, syngeneic H-2d (Balb/Cl7) or allogeneic
-2b(MC57) target cells were infected with LCMV at a
.o.i. of 1, or uninfected target cells coated were with
CMV peptide NP aa 118–126 (Whitton et al., 1989) [H-2d
(Ld) restricted] as described (Oldstone, 1987; von Herrath
et al., 1994a,b; Whitton et al., 1993). For in vitro CTL
affinity assessment, peptide-coated target cells at vary-
ing log dilutions were used, unless otherwise indicated.
Splenocytes harvested 28 days after the last lipopeptide
vaccination were stimulated from all groups of mice
simultaneously in vitro for 8 days (von Herrath et al.,
1994b) and were used as effectors at an E:T ratio of 5:1.
pCTL measurements. For precursor frequency analy-
sis, always harvested 28 days after the last lipopeptide
vaccine, splenic lymphocytes were diluted serially and
cultivated in 96-well flat bottom plates in the presence of
T cell growth factor, LCMV-infected macrophages (irra-
diated with 2000 rad), and syngeneic irradiated spleen-
feeder cells, or syngeneic feeder cells coated with 1025
M LCMV NP H-2d peptide (105/well) as described (von
errath et al., 1995, 1996). After 5 to 9 days, each well
as assayed for CTL lysis (described above) on target
ells that were uninfected or infected with LCMV or
eptide coated/uncoated. The fraction of negative cul-
ures (percentage lysis ,3 standard errors above back-
round lysis of uninfected target cells) was determinedor each dilution and correlated on a semilogarithmic
cale with the number of splenocytes per well. Theumber of pCTL was determined according to the for-
ula pCTL(f) 5 {4.6-ln (percentage negative wells)}/num-
er of splenocytes per well.
Cytokine analysis. Lymphoid cells were harvested
rom spleens 60 days after LCMV infection or from per-
istently infected mice at 2 months of age. APCs in the
ssay consisted of 2 3 105 irradiated syngeneic spleen
cells per well or APCs from the native spleen population
(for assays quantitating not proliferation but cytokine
production in the supernatant of proliferating cultures)
infected with LCMV or coated with LCMV NP peptide
(see CTL assay section). The medium was RPMI con-
taining 7% fetal calf serum and glutamine.
Assessment of cytokine production by ELISA. Cyto-
kines (IL-4, IL-6, IL-10, IL-2, and IFN-g) were detected
using the ELISA (PharMingen, San Diego, CA). Briefly,
96-well plates were coated with the respective capture
antibodies for IL-2, IL-4, IL-6, IL-10, and IFN-g diluted
t 2 mg/ml. After overnight incubation at 4°C, plates
ere washed four times with PBS–Tween 20 (.05%)
nd preincubated with PBS containing 10% FCS for 1 h
t room temperature (RT). Tissue culture supernatants
nd standards were added at various dilutions in PBS
ith 10% FBS, .05% Tween 20, and plates were incu-
ated 2 to 4 h at RT. Thereafter, plates were washed
our times with PBS–Tween, and the respective detec-
ion antibodies for the cytokines were added at 1
mg/ml in PBS–Tween containing 10% FCS. Plates were
ncubated at RT for 1 h and washed four times in
BS–Tween before streptavidin-peroxidase conjugate
Boehringer, Indianapolis, IN) was added at 1:1000
ilution. After a 30-min incubation at RT, the color-
ubstrate solution (ABTS) was added and left on the
lates for 10 to 30 min. Plates were then counted in an
LISA reader at 405 nm.
Adoptive transfers. Spleens from mice persistently in-
ected with LCMV or adult mice (8 to 10 weeks old)
noculated ip with 2 3 105 PFU of LCMV were harvested
60 days after birth or inoculation, then prepared as sin-
gle-cell suspensions by being pressed through a fine
steel mesh and freed from RBC by addition of 0.83%
ammonium chloride. If required, the mixture was passed
through a 70 mM pore-size nylon filter to remove residual
tissue and cell aggregates. In some experiments, CD81
T cells were depleted prior to transfer. Transfer recipi-
ents were irradiated with 300 rad immediately before
lymphoid populations were administered ip at the con-
centrations stated under Results.
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